Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | AHR | P35869 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750407 | 0.90 | ACSS2 (0.47) | CYP17A1AHRCYP19A1ACSS2CYP1A2 | |
| SCHEMBL5752572 | 0.86 | CYP19A1 (0.53) | CYP17A1AHRCYP3A4CYP19A1 | |
| SCHEMBL5753491 | 0.82 | CYP17A1 (0.47) | CYP17A1AHRCYP3A4CYP1A2CYP2A6 | |
| SCHEMBL5754537 | 0.78 | CYP17A1 (0.44) | CYP17A1AHRCYP3A4CYP19A1CYP1A2 | |
| SCHEMBL5751050 | 0.78 | CYP17A1 (0.44) | CYP17A1AHRCYP3A4CYP1A2CYP2A6 | |
| SCHEMBL5678311 | 0.78 | CYP17A1 (0.61) | CYP17A1CYP3A4 | |
| SCHEMBL5754031 | 0.77 | CYP17A1 (0.43) | CYP17A1AHRCYP3A4CYP1A2CYP2A6 | |
| SCHEMBL5678169 | 0.76 | CYP17A1 (0.42) | CYP17A1AHRCYP3A4CYP1A2CYP2A6 | |
| SCHEMBL5754377 | 0.76 | CYP17A1 (0.41) | CYP17A1CYP3A4CYP1A2CYP2A6 | |
| SCHEMBL5755529 | 0.75 | CYP17A1 (0.46) | CYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885AHR 89/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.